Ung thư biểu mô tế bào gan giai đoạn tiến triển: liệu có thể chỉ định điều trị tại chỗ?

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Thị Hoàng Anh Châu, Trọng Bỉnh Lê

Ngôn ngữ: Vie

Ký hiệu phân loại: 572 Biochemistry

Thông tin xuất bản: Tạp chí Y Dược học Huế 2023

Mô tả vật lý: 85-90

Bộ sưu tập: Metadata

ID: 410085

Thêm vào giỏ Liên kết toàn văn

Tóm tắt
Chủ đề

Phân loại bệnh nhân ung thư biểu mô tế bào gan (UTBMTBG) giai đoạn tiến triển có thể chỉ định điều trị tại chỗ. Đối tượng và phương pháp nghiên cứu: 62 bệnh nhân UTBMTBG giai đoạn tiến triển tại Bệnh viện trường Đại học Y - Dược Huế từ 11/2020 đến 8/2022. Mô tả đặc điểm hình ảnh cắt lớp vi tính, xét nghiệm và toàn trạng (ECOG PS). Chẩn đoán UTBMTBG theo hướng dẫn của Bộ Y tế 2020. Tiêu chuẩn để xem xét điều trị tại chỗ gồm kích thước u ≤ 10 cm, huyết khối tĩnh mạch cửa type I, Child-Pugh A và PS 0 - 1. Kết quả: Tuổi trung bình: 59,4 ± 11 tuổi, nam/nữ: 9/1. Kích thước u trung bình: 10,2 ± 4,2 cm
64,5% bệnh nhân có ECOG PS 0 - 1
69,4% Child-Pugh A
59,7% ALBI II. Có 8/62 (12,9%) có thể chỉ định điều trị tại chỗ kết hợp hoá trị toàn thân. Kết luận: Bệnh nhân UTBMTBG giai đoạn tiến triển không đồng nhất về đặc điểm hình ảnh, chức năng gan và toàn trạng. Việc phân loại chi tiết bệnh nhân ở giai đoạn này giúp tối ưu hoá chiến lược điều trị., Tóm tắt tiếng anh, To classify patients with advanced hepatocellular carcinoma (HCC) who might benefit from locoregional therapies. Materials and methods: Data of 62 patients with advanced HCC from 11/2020 to 08/2022 at Hue University of Medicine and Pharmacy Hospital were analyzed. Computed tomography (CT) findings, all liver function tests and performance status (PS) were documented. Criteria for considering locoregional therapies include tumor size ≤ 10 cm, segmental portal vein thrombosis, Child-Pugh A and PS 0 - 1. Results: Mean age: 59.4 ± 11 years, male: female ratio 9:1. Average tumor size: 10.2 ± 4.2 cm. 64.5% of patients had PS 0 - 1
69.4% had Child-Pugh A
59.7% had ALBI grade 2. There was a positive correlation between ALBI score and Child-Pugh score (p <
0.01). ECOG PS was associated with Child-Pugh classification (p <
0.01) and ALBI grade (p <
0.01). There was an association between portal vein thrombosis and tumors size (p <
0.05). 8/62 (12.9%) patients met the criteria of locoregional therapies. Conclusion: Advanced HCC was a heterogeneous population in terms of CT findings, liver function tests and PS. Detailed classification of this subgroup could optimize treatment outcomes.

Tạo bộ sưu tập với mã QR